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Abstract
The absolute or relative lack of insulin is the key factor in the pathogenesis of diabetes melli-
tus. Although the connection between loss of function mutations of theWFS1 gene and DID-
MOAD-syndrome including diabetes mellitus underpins the significance of wolframin in the
pathogenesis, exact role ofWFS1 polymorphic variants in the development of type 1 and
type 2 diabetes has not been discovered yet. In this analysis, 787 patients with diabetes
and 900 healthy people participated. Genotyping of the 7WFS1 SNPs was carried out by
TaqMan assays. Association study was performed by χ2-test in combination with correction
for multiple testing. For functional analysis, the entire 3’ UTR of theWFS1 gene was sub-
cloned in a pMIR-Report plasmid and relative luciferase activities were determined. Linkage
disequilibrium analysis showed a generally high LD within the investigated region, however
the rs1046322 locus was not in LD with the other SNPs. The two miR-SNPs, rs1046322
and rs9457 showed significant association with T1DM and T2DM, respectively. Haplotype
analysis also confirmed the association between the 3’ UTR loci and both disease types. In
vitro experiments showed that miR-185 reduces the amount of the resulting protein, and
rs9457 miRSNP significantly influences the rate of reduction in a luciferase reporter assay.
Genetic variants of theWFS1 gene might contribute to the genetic risk of T1DM and T2DM.
Furthermore demonstrating the effect of rs9457 in binding of miR-185, we suggest that the
optimal level of wolframin protein, potentially influenced by miR-regulation, is crucial in nor-
mal beta cell function.
Introduction
Diabetes mellitus is a group of pathogenically heterogeneous diseases sharing the trait of abso-
lute or relative insufficiency of insulin effect. Common forms of the disease are type 1 (T1DM)
and type 2 diabetes mellitus (T2DM). T1DM results from autoimmune β-cell destruction lead-
ing to insulin deficiency, whereas type 2 diabetes (T2DM) is the end point of a progressive
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insulin secretion defect on the background of insulin resistance. Both T1DM and T2DM are
considered to be complex diseases caused by multiple environmental and genetic risk factors.
Polymorphisms and mutations of genes associated with other, much rarer monogenic forms of
diabetes have been in the focus of research for many years. One of these illnesses is the Wol-
fram- or DIDMOAD-syndrome, characterized by diabetes insipidus, non-autoimmune and
non-HLA-linked insulin dependent diabetes mellitus together with progressive degeneration
of beta cells[1], optic atrophy and deafness[2]. The mutated gene causing the disease was
denominatedWFS1 and is located on chromosome 4 region p16[2]. It was suggested that poly-
morphisms of theWFS1 resulting in minor modulation of the gene function instead of com-
plete loss might be in the genetic background of the common, polygenic forms of diabetes
(T1DM and T2DM). Meta-analysis of association studies revealed that the rs1046320 and
rs10010131 SNPs were significant risk factors of T2DM[3]. The two SNPs were in strong link-
age disequilibrium with each other, and although no biological effect could be demonstrated, it
is notable that the rs1046320 polymorphism is located in the 3’ UTR of theWFS1 gene.
Significance of the miRNA system in the fine regulation of protein synthesis has recently
been discovered. Although the principle of miRNA-action is their binding to the 3’UTR of tar-
get genes, prediction of this interaction based on solely sequence alignment is doubtful. 355
miRNAs were suggested to have a binding site in theWFS1 3’UTR in silico by the miRWalk
database[4], however this interaction could be confirmed by molecular methods only for miR-
21 and the members of the hsa-let-7 family. Similarly 11439 genes (includingWFS1) were pre-
dicted to be the putative target of miR-185, whereas only 33 (excludingWFS1) have been con-
firmed in vitro so far. Considerable data suggest that miRNAs have a direct role in insulin
secretion and production, pancreatic islet development, insulin action and indirectly control
glucose and lipid metabolism[5]. The miRWalk database suggested a connection between dia-
betes mellitus and 140 miRNAs. Although miR-185 was not among these hits, it was demon-
strated by a recent study that both miR-185 and miR-668 were expressed in pancreatic islets
[6]. Moreover, analyzing numerous tissues it was observed that miR-185 was abundant, high
expression level was detected in the brain, kidney, lung, placenta, prostate, spleen and thyroid
glands[7]. On the other hand miR-668 showed an islet-specific expression[6]. Our earlier study
[8] revealed that miR-668 not only bound to the 3’UTR of theWFS1 gene, but this connection
was influenced by the rs1046322 SNP, which showed a significant association with diabetes
mellitus according to our current findings (Tables 1, 2, 3 and 4).
In this study we demonstrate an association between both types (T1DM and T2DM) of
diabetes mellitus and SNPs in theWFS1 gene. Three of the investigated polymorphisms
(rs1046320 A/G, rs1046322 A/G and rs9457 C/G) are located in the 3’UTR of the gene,
rs1801208 A/G is in exon 8, whereas rs6824720 A/G, rs10010131 A/G and rs13147655 A/G are
in intron 1, 4 and 5 respectively. We show that besides the rs1046322 locus, described earlier
[8], the rs9457 SNP also influences miRNA binding in an in vitro system. These data might
help in elucidating the molecular background of the disease and might contribute to the elabo-
ration of novel, alternative therapeutic approaches.
Materials and Methods
Participants, DNA-purification
407 patients diagnosed with T1DM (from the 3rd Department of Internal Medicine, Szentá-
gothai Knowledge Center, Semmelweis University, 46.9% female, 53.1% male, disease onset at
the age of 32.1 ± 10.5 years) and 380 patients with T2DM (from the 2nd Department of Internal
Medicine at the Semmelweis University, 57.9% female, 42.1% male, disease onset at the age of
48.0 ± 12.7 years) participated in the study. The 900 healthy volunteers (59.0% female, 41.0%
Association of WFS1 SNPs and Diabetes
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male, mean age: 39.0 ± 13.1 years) were recruited by the Institute of Psychology, Eötvös Lor-
ánd University. The study protocol was approved by the Local Ethical Committee (ETT-TU-
KEB ad.328/KO/2005, ad.323-86/2005-1018EKU from the Scientific and Research Ethics
Committee of the Medical Research Council). To address the issue of population stratifica-
tion, the participation was restricted to subjects of Hungarian origin, thus creating an ethni-
cally homogenous population. All participants signed written informed consent before
providing DNA sample for genetic testing. Buccal epithelial cells were collected by swabs in
duplicates (two swabs per sample and two samples per person). DNA purification was initi-
ated by the incubation of the buccal samples at 56°C overnight in 0.2 mg/ml Proteinase K cell
lysis buffer. It was followed by denaturing the proteins with saturated NaCl solution. Finally,
DNA was precipitated using isopropanol and subsequently by 70% ethanol. DNA pellet was
resuspended in 100 μL 0.5× TE (1× TE: 10 mM Tris pH = 8.0; 1 mM EDTA) buffer. Concen-
tration of the DNA-samples was measured by NanoDrop1000 spectrophotometer.
SNP Genotyping
Seven SNPs in theWFS1 gene were genotyped by using pre-designed TaqMan assays from Life
Technologies (rs6824720: C__30903802_10; rs10010131: C__30473796_10; rs13147655:
C__22272143_10; rs1801208: C___2401737_10; rs1046320: C___2873369_10; rs1046322:
C___8841086_1_; rs9457: C___2873371_10). These assays contained the two primers and
allele-specific fluorescent probes labeled by FAM and VIC, respectively. Reaction mixtures
contained these primer–probe premixes, the TaqMan
1
Genotyping Master Mix (including
AmpliTaq Gold
1
DNA-polymerase, deoxyribonucloside-triphosphates and buffer) according
to manufacturer’s instructions as well as approximately 4 ng genomic DNA in a final volume
of 6 μL. A 7300 Real Time PCR instrument was used for amplification. Thermocycle was
started by activating the hot start DNA-polymerase and denaturing genomic DNA at 95°C for
10 minutes. This was followed by 40 cycles of denaturation at 95°C for 15 sec, and combined
annealing and extension at 60°C for 1 minute. Real-time detection was carried out during the
latter step for higher sensitivity and reliability to verify the results of the subsequent post-PCR
plate read and automatic genotype call.
Genotype data in “ped” format are available as S1–S4 Tables.
Table 2. Association analysis of the investigatedWFS1 SNPs and diabetesmellitus by Cochran–
Armitage trend test.
SNP T1DM T2DM DM
rs6824720 0.173 0.006 0.038
rs10010131 0.121 1.810−4 0.002
rs13147655 0.064 7.110−4 0.003
rs1801208 0.932 0.551 0.372
rs1046320 0.726 2.210−4 0.020
rs1046322 2.610−8 0.003 9.210−7
rs9457 0.031 8.710−4 8.510−4
The table depicts the p values of statistical significance. Bold numbers show nominally significant results,
underlined p values are significant using FDR approach, whereas double underlined numbers mean
significant results after Bonferroni correction for multiple testing. Analyses were carried out in both disease
types (T1DM: N = 407, control: N = 817; T2DM: N = 380, control: N = 892) as well as in the combined
patient group (DM: N = 787, control: N = 900).
doi:10.1371/journal.pone.0139519.t002
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Plasmid construction
The full length 3’ untranslated region (3’UTR) of theWFS1 gene was amplified by PCR using
a DNA-sample of an individual with known rs9457 (homozygous CC) genotype. The following
primers were used: forward primer: 5’ TCG GCG GAG CTC GGA TGG TCC GCC ACG AGG
AGC 3’ (where the Sac I site is underlined) and reverse primer: 5’ AAA GGA AAG CTT GCG
CTG CAG GTT CCA CCA GAG G 3’ (where the Hind III site is underlined). The PCR prod-
ucts were digested with Sac I andHind III and were cloned downstream of the firefly luciferase
gene in pMIR-Report plasmid (pMIR-REPORT miRNA Expression Reporter Vector System;
ABI) by T4 DNA ligase (New England BioLabs) using standard protocols. The generated
reporter construct (denoted as C) carried the C (risk) allele, the other one (denoted as G) carry-
ing the protective G allele was generated by Quick Change Lightning (Stratagene) site directed
mutagenesis. A reference construct (referred to as Seed) contained a completely modified seed
region: site-directed mutagenesis was employed to modify the appropriate segment of this con-
struct. A control construct contained a different DNA-insert with the same length lacking any
sequence complementary to miR-185 (denoted as Control). All constructs were confirmed by
DNA sequencing.
MiRNA binding assay
Human Embryonic Kidney cell line (HEK293T) was cultured in DMEMmedium (Invitrogen
—Gibco), supplemented with 10% bovine fetal serum (Lonza). The cells were maintained at
37°C in an atmosphere of 5% CO2. For miRNA assays the cells were seeded into 24-well plates
and incubated for 24 hours before transfection. Subsequently, 0.05 μg of the luciferase reporter
construct were cotransfected with 0.2 μg β-galactosidase plasmid (Ambion) and 5 pmol of
miR185 and/or miR668 (Sigma-Aldrich) using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instruction. When investigating the effect of the presence or absence of
miR185 and miR668, miR20b was used as supplement to use the same amount of total miRNA
in each sample to avoid any spurious effect. Cells were collected 48 hours after transfection,
washed with PBS, then extracted by three consecutive freeze–thaw cycles and subsequent cen-
trifugation. Supernatants were used for enzyme activity measurements. Luciferase activity was
measured by adding 60 μl Luciferin reagent (0.16 mg/ml Luciferin K, 20 nM Tricine, 2.6 nM
MgSO4, 0.1 nM Na2EDTA, 33.3 nM DTT, 0.27 nM Li3CoA and 0.53 nM Na2ATP) to 12 μl of
each cell extract. Luminescence was measured using a Varioskan multi-well plate reader
(Thermo Fisher Scientific, Inc.). Values for luciferase activity were normalized to β-galactosi-
dase activity (measured by standard protocol using the same Varioskan plate reader in pho-
tometry mode). Each experiment was independently repeated three times, and each sample
was studied in triplicate.
Statistical analysis
The Hardy–Weinberg equilibrium (HWE) for genotype distributions was assessed by χ2-test.
No significant difference (p> 0.1) could be observed between the measured and expected
genotype frequencies in the control group for any of the investigated SNPs. The frequency of
both T1DM and T2DM is similar in females and males, and both disease types can develop at
any age, although T1DM is more characteristic in juveniles, whereas symptoms of T2DM usu-
ally appear in patients older than 40. Despite, age- and sex-matched study design was used in
each analysis to rule out any spurious association. Allele-wise association analysis and geno-
type-wise tests using dominant and recessive models were carried out by comparing the allele
or genotype frequency values of each polymorphism in the patient and control group using
SPSS v17.0 and HaploView v4.2[9]. GWASpi[10] was applied to perform Cochran–Armitage
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trend test[11]. Correction for multiple testing was carried out to avoid false positive results
using two different approaches. False Discovery Rate (FDR) was calculated by Microsoft Excel,
results were verified using a web-based tool (http://www.sdmproject.com/utilities/?show=
FDR) [12]. The more stringent Bonferroni correction was also applied, the accepted level of
statistical significance was 0.05 / 84 = 5.95  10−4, as 7 loci and 3 patient categories (T1DM,
T2DM and combined) were analyzed in 4 different approaches. Haplotype analysis was carried
out by HaploView v4.2[9]. The same software package was used to linkage disequilibrium anal-
ysis. ANOVA of the luciferase assays was carried out using GraphPad InStat (version 3.05).
Results
Marker selection
Seven SNPs of theWFS1 gene were recruited in our study. Three (rs1046320, rs1046322 and
rs9457) of them were located in the 3’ UTR of the gene. The rs1046322 and rs9457 polymor-
phisms were suggested to be miR-SNPs altering the binding site of the miR-668 and miR-185
respectively by the Patrocles[13] and PolymiRTS[14] databases. Moreover, putative regulatory
effect of the rs1046322 site has previously been demonstrated by in vitro luciferase reporter sys-
tem[8]. The rs1046320 SNP was shown to be in association with type 2 diabetes mellitus, how-
ever no biological function could be detected[3]. The rs687420, rs10010131 and rs13147655
polymorphisms are intronic variants, whereas rs1801208 is located in the last exon of the gene.
These sites have been selected based on literature data, and our earlier thorough SNP analysis
of theWFS1 gene including 17 polymorphic loci[8] recruiting at least one polymorphism from
each haplotype block.
Linkage disequilibrium analysis
Fig 1 Panel A and B show the pairwise linkage disequilibrium (LD) analysis based on our popu-
lation including healthy control subjects and patients demonstrating Lewontin’s D’ and R2 val-
ues, respectively. These results were in good agreement with the LD analysis using the data
set of the 1000 Genomes Project (Fig 1 Panel C and D). Generally a high level of LD can be
observed in the gene region, although it is notable that the rs1046322 polymorphism was not
in linkage disequilibrium with the other sites. Moreover the high D’ values in combination with
the low R2 values regarding the rs1801208 polymorphism show a partial linkage disequilibrium
of this locus with other SNPs, demonstrating the occurrence of three and the lack of one haplo-
type out of the four theoretical pairwise allele combinations.
Association studies
Table 1 summarizes the results of the case-control study in an allele-wise setting. Analyses
were carried out for both diabetes types as well as for the combined patient group using age-
and sex-matched controls. Interestingly the risk allele was the same for the type 1 and the type
2 forms of the disease, and it is also remarkable, that it was only the rs1046322 SNP, at which
this variant was the minor allele. It is also notable that polymorphisms in rather different loca-
tions of the gene associated with diabetes mellitus, although no complete linkage disequilib-
rium could be shown in this region. However the lowest p values of statistical significance
could be detected in case of two 3’UTR SNPs. The rs1046322 and rs9457 polymorphisms
showed nominally significant (p< 0.05) association in all three (type 1, type 2 and combined)
analyses, which remained significant in all cases after FDR correction for multiple testing. The
association between the rs1046322 polymorphism and T1DM as well as that between rs9457
SNP and T2DM could be declared even using the more stringent Bonferroni approach
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(accepted level of significance: p 5.95  10−4). Moreover, the rs10010131, the rs13147655 and
the rs1046320 SNPs were also found to significantly associate with type 2 diabetes even using
FDR or Bonferroni correction.
The Cochran–Armitage trend test was employed to extend the association study in a geno-
type-wise manner (Table 2). In agreement with the allele-wise test, no association could be
detected between the rs1046320 locus and T1DM (p = 0.726). The major effect of the rs1046322
SNP in T1DM was also confirmed (p = 2.639  10−8), whereas a weak nominal association
Fig 1. Linkage disequilibrium analysis of the investigatedWFS1 SNPs. Upper panels indicate the chromosomal positions of the polymorphisms, below
the pairwise linkage disequilibrium data of the SNPs are demonstrated. Lewontin’s D’ (Panels A and C) and R2 values (Panels B and D) calculated based on
our genotype data (Panels A and B) as well as based on the data obtained from the 1000 Genomes Project (Panels C and D) are shown. Dark background
and D’ or R2 = 100 values mean strong linkage disequilibrium between the two appropriate loci. (Colored version of the figure is available online.)
doi:10.1371/journal.pone.0139519.g001
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(p = 0.031) could be observed between rs9457 locus and the type 1 disease form. The Cochran–
Armitage trend test detected association in the T2DM group in case of 6 SNPs, all of them
remained significant using FDR correction. The allele- and genotype-wise analyses were in good
agreement in the combined diabetes group as well. Strong association could be detected in case
of two 3’UTR polymorphisms (rs1046322 and rs9457), the former one remained significant
even using Bonferroni correction.
To further analyze association between the 7WFS1 SNPs and diabetes mellitus in a more
detailed and systematic way, genotype-wise tests were carried out applying two different
approaches (Tables 3 and 4). Frequency values of the genotype consisting of both risk alleles
were computed for all loci in each patient group using the recessive model. In this setup a
remarkably high odds ratio (7.641) was observed in case of the rs1046322 SNP in the T1DM dis-
ease group, whereas the significant association between rs10010131, rs1046320, rs9457 polymor-
phisms and T2DMwas also confirmed. When using the dominant model, i.e. comparing the
frequency of risk allele carriers and noncarriers, the effects detected previously could be observed.
Association was found between the rs1046322 locus and T1DM, as well as between all three 3’
UTR SNPs and the rs13147655 polymorphism and type 2 disease form using FDR correction,
however none of these results remained significant by the stringent Bonferroni method. This
observation shows that the effect of the risk allele is more pronounced in homozygous form sug-
gesting that the recessive model is more appropriate in this case, however it can also be remarked
that pure recessive or dominant inheritance can only be expected in case of monogenic diseases.
Based on the putative synergistic effect of the three 3’UTR SNPs (rs1046320, rs1046322 and
rs9457) in translational regulation, these polymorphisms were included in a haplotype-wise
association study. Investigation of the patient group with type 1 diabetes mellitus confirmed the
major effect of the rs1046322 SNP. Frequency of the haplotypes containing the risk (“A”) allele
of this site in combination with the risk variant of one or both SNPs (Table 5) was significantly
higher in the patient group. This resulted in an outstanding odds ratio value, which was above 3
in all cases. Similar leader effect of a single polymorphism could not be observed in case of type
2 diabetes. The “AC” haplotype of the rs1046320 and rs9457 SNPs showed a highly significant
association with the disease, on the other hand odds ratio was the lowest in case of this combina-
tion, and it is also remarkable that these two polymorphisms are in linkage disequilibrium with
each other, which can also contribute to the observed low statistical p value of the χ2-probe.
In vitromiRNA binding assay
Putative role of the rs9457 locus on miRNA binding was analyzed by in vitro luciferase assay,
as according to the prediction of the PolymiRTS[14] database, this SNP is located in the bind-
ing site of the seed sequence of microRNA-185 (miR-185). The 3’UTR region of theWFS1
gene was subcloned in a pMIR-Report luciferase reporter vector, construct with the “G” allele
at the rs9457 locus was created by site directed mutagenesis. The same approach was used to
generate the “seed mutant” construct, which lacked the entire binding site of the seed sequence
of miR-185. Moreover a construct without any binding site of miR-185 (referred to as “Con-
trol”) was also used. Luciferase enzyme levels were normalized to β-galactosidase activities.
The lowest relative luciferase activity (35% of the “Control”) could be measured with the con-
struct containing a “C” allele of the rs9457 polymorphism (Fig 2). Interestingly a single mis-
match caused by the SNP resulted in a more, than 1.7 times increase (p< 0.05) in luciferase
level, and this value was practically identical with the activity of the “seed” construct. It might
be related to the finding of the in silico sequence alignment, which showed only 6 complemen-
tary bases out of the 7 nucletotides of the seed sequence in case of the “C” allele, and the “G”
variant adds a further mismatch into the region (Fig 2, Panel B), resulting in a hypothetically
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even weaker interaction between miRNA and mRNA. The putative role of miRNA-based regu-
lation was further analyzed by investigating the haplotype containing the rs1046320 “A”–
rs1046322 “A”–rs9457 “C” variants, which are the risk alleles of diabetes (Table 5) according to
our association study. Earlier we demonstrated that the rs1046322 locus altered the binding
efficiency of miR-668[8], now the combined effect of miR-185 and miR-668 was assessed. Rela-
tive luciferase activities were measured in the presence or absence of any or both of miR-185
and miR-668, respectively. Presence of both miRNAs resulted in a 0.71 relative luciferase activ-
ity (p = 0.013) compared to the reference sample (without miR-668 and miR-185). Application
of only miR-185 caused a somewhat smaller effect (relative activity: 0.78, p = 0.036). On the
other hand miR-668 did not result in a significant decrease (relative activity: 0.89, p = 0.251) in
relative luciferase level. This observation might be explained by the fact that the rs1046320 “A”
allele leads to a mismatch in the binding site of the seed region of miR-668, thus its weaker
binding and milder effect can be expected.
Discussion
Role of wolframin in the development of diabetes mellitus
Relationship between wolframin and diabetes mellitus has been suggested at numerous levels.
Although theWFS1 gene is abundant, high expression level was detected in pancreatic islets[2]
Fig 2. Analysis of the effect ofWFS1 rs9457 SNP onmiR-185 binding by luciferase reporter assay. The
entire 3’ UTR region of theWFS1 gene was subcloned into the pMIR luciferase riporter vector. Transient
transfection were performed in HEK293 cells, for details, see Method section. Luciferase activity values
normalized to β-galactosidase activity were measured, Panel A represents average ± SD values of three
independent experiments. (*** p < 0.001). The “C” luciferase construct harbored the rs9457 C allele,
whereas the “G” contained the rs9457 G variant. “Seed” construct was generated by changing all seven
nucleotides in the core binding site of WFS1 3’ UTR region. “Control” construct contained a different DNA-
insert with the same length lacking any sequence complementary to miR-185. Panel B demonstrates the
sequence alignment of miR-185 and its binding site in theWFS1 3’ UTR. Mismatches are shown by the
shifted nucleotides of the miRNA, the rs9457 locus is shown by dark background.
doi:10.1371/journal.pone.0139519.g002
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and in insulinoma β-cell lines[15]. The 100 kDa wolframin protein possesses 9 transmembrane
polypeptide regions and is located in the membrane of the endoplasmic reticulum (ER), the
N-terminal of the protein is oriented in the cytoplasm, whereas the C-terminal is in the lumen
of the ER. Its structure and localization suggest that the protein might play a role in membrane
transport and might contribute to the Ca2+ homeostasis of the ER[16]. This was confirmed by
the observation of[17] that wolframin expression increases the Ca2+ concentration of the cyto-
sol in Xenopus oocytes. Connection between ER homeostasis and diabetes mellitus is well
known. The increased insulin production caused by insulin resistance in T2DM leads to
chronic ER stress and this contributes to the death of β-cells by apoptosis. It was demonstrated
that glucose induced insulin secretion leads to increased WFS1 expression in wild type mice,
whereas ER stress and β-cell dysfunction can be observed inWFS1 knock-out animals[18].
Our data further support the connection between wolframin and diabetes mellitus at a
genetic level. Loss of function mutations are well known causes of the monogenic DIDMOAD
syndrome[2], as well as some SNPs of the gene have been shown to be in association with
T2DM[3]. Our data confirm the association between the gene and the disease, moreover
extend this knowledge in some aspects. First, it is important to note that our study included a
large group of both T1DM and T2DM patients and we detected association with both disease
types. The rs1046322 SNP was found to be a strong risk factor of T1DM and showed a weaker
association with T2DM as well. The rs9457 SNP was demonstrated to be in stronger associa-
tion with the type 2 form of the disease, and the association between rs10010131 and T2DM[3]
was confirmed. Haplotype analysis revealed the significance of the 3’UTR polymorphisms
in both forms of the illness. Although the symptoms and clinical appearance of T1DM and
T2DMmight be rather different, this observation is in agreement with the accelerator hypothe-
sis of Wilkin[19] suggesting that patomechanism and some molecular dysfunctions overlap in
the two disease types. On the other hand our results suggested and supported molecular and
functional connection between the identified SNPs and the disease. Our in vitromolecular
assays demonstrated that the rs1046322[8] and the rs9457 SNPs are located in miRNA binding
sites and might alter the binding efficiency of the corresponding miRNA. This effect might
play a role in vivo resulting in slightly different wolframin levels in case of the presence of dif-
ferent allele and haplotype patterns.
MiRNA regulation
Numerous evidences suggest, that the impaired regulation of wolframin level can be one of the
molecular mechanisms leading to diabetes. MiRNAs are important components of this regula-
tory network, and the multiple connection between miRNAs and the disease has recently been
demonstrated[20]. MiRNAs were shown to influence ADP: ATP ratio[21, 22], exocytosis of
insulin granules[23] and insulin synthesis[24]. MiRNAs were also suggested to contribute to
the development of insulin resistance through the protein kinase B / GLUT 4 translocation
pathway[25–27]. Altered expression of miRNAs was observed in both T1DM[28] and T2DM
[29] including miR-185, which was shown to influence β-cell activity by targeting the mRNA
of suppressor of cytokine signaling 3 (SOCS3)[30]. This is observation underlines the fact that
the miRNA regulation network is rather complex. There are several miRNAs that influence the
translation of the same target. It is notable that we earlier described an in vitro interaction
betweenWFS1 3’ UTR and miR-668[8], and demonstrated in the current project that the
rs1046322 SNP influencing the affinity of miR-668 toWFS1mRNA showed a strong associa-
tion with diabetes mellitus. It was also observed that the WFS1 3’ UTR with the risk haplotype
(rs1046320 “A”–rs1046322 “A”–rs9457 “C”) is sensitive to both miR-185 and miR-668,
although the effect of miR-185 seemed to be stronger in the in vitro luciferase assay. Moreover,
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one miRNA can be the regulator of numerous mRNAs. The data of Bao[30] and our results
show, that these different pathways can be in the background of the same phenotype, as miR-
185 is suggested to be related to diabetes mellitus via two different (SOCS3 andWFS1) targets.
Taking these data together, interaction of miRNAs andWFS1 could be of great importance
in the molecular background of diabetes mellitus. This is further supported by a recent com-
prehensive study focusing on the miRNA profile of pancreatic β-cells[6]. Comparison of the
mRNA targets of islet specific miRNAs and candidate genes of T2DM based on genome-wide
association studies resulted in six hits includingWFS1 underlining the putative in vivo rele-
vance of the findings of our results obtained by in vitro luciferase assays.
Linkage disequilibrium study
Linkage disequilibrium analysis is an important supplement of association studies in several
aspects. On one hand, loci in LD might help to identify candidate genes or chromosome
regions associating with a phenotype, on the other hand although tag SNPs show statistical
association, despite they are often not the polymorphisms that possess biological effect. Our
earlier study analyzed 17 SNPs of theWFS1 gene in another sample set[8], these results were
used for SNP selection in this study. LD analysis of the 7 polymorphisms in our current work
was in good agreement not only with the results of our earlier findings, but also with the LD
analysis of the genotype data available from 1000 Genomes Project. These results suggest two
observations. First, pairwise D’ and R2 values of the rs1046322 SNP with other loci are low
suggesting that this SNP is not a genetic marker only, but presumably possesses direct biolog-
ical effect. This is in good agreement with our earlier observations[8] demonstrating the
effect of rs1046322 SNP on the alteration on binding efficiency of miR-668 in vitro, and it is
notable that this miR was shown to be specific for pancreatic islets[6]. It is also in concor-
dance with our data suggesting the functional role of rs9457 polymorphism in miR-185 bind-
ing, which miR shows a high expression level in islet cells, and these observations support the
importance of miR-based regulation of wolframin level in the molecular background of dia-
betes. On the other hand, rs9457 SNP is in LD with several other loci, such as rs1046320.
This could clarify the results of an earlier study[3] demonstrating an association of the
rs1046320 SNP with diabetes, however failing to show any functional effect of this locus.
It might be explained by our findings: as the two sites are in linkage disequilibrium, the
rs1046320 polymorphism can be considered to be a genetic marker of the rs9457 site, which
possesses a molecular function.
In conclusion, our study not only confirms that polymorphic variants of theWFS1 gene are
the genetic components of T2DM but also suggests loci that might play a molecular role in the
development of the illness. Moreover, we demonstrated that these SNPs can also contribute to
the development of T1DM form of the disease. Besides, we showed association between novel
3’ polymorphisms and diabetes mellitus, these loci were demonstrated to be miR-SNPs altering
the binding efficiency of miR-185 and miR-668. These results might contribute to the under-
standing of molecular processes in the background of diabetes mellitus, which could be of clini-
cal significance providing the bases of novel approaches of therapy or secondary prevention.
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This file contains the genotype data of the combined group of patients with either type of dia-
betes mellitus and the control samples.
(PED)
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